Tagged with R

Janssen John O’Hara is the general manager and vice president of Janssen’s facilities in Puerto Rico as well as the head of the Janssen campus. He discusses the affiliate’s rapid growth curve in the last three years through its dedication towards people, processes and community. What are the origins of Janssen’s…

Pharmacy José Pérez de Gracia, president of Farmacias Plaza, discusses the environment between multinational chains and local pharmacies as well as his own plan for extended growth throughout Puerto Rico in the future. A couple of multinational pharmacy chains could be said to control a large monopoly of the market share…

consultancy Prevention versus remediation is the name of the game in regulatory and compliance issues for pharmaceutical manufacturers; the cost of non-compliance is much higher than investing proactively in compliance. Elizabeth Plaza, founder and chairwoman of the board of Puerto Rican-based regulatory and compliance consultancy Pharma-Bio Serv, discusses how her company…

Roche Miguel Centeno, general manager and head of Roche Diabetes Care in Puerto Rico, highlights the affiliate’s strong manufacturing performance in the area of diabetes care (DC) blood glucose test strips above its competitors.   Can you provide us with an overview of the current state of the medical device and…

IMS IMS Health recently released its World Review 2015. The new general manager of North Latin America shares the company’s assessment on the performance of the Mexican pharmaceutical market for 2014, what trends are shaping the industry as well as the moderate, yet positive outlook for 2015. How would you assess…

association The industry of medical devices is still not very well understood. Pablo Dávila shared with us his overview on the Mexican market, how the Mexican Association of Innovative Medical Device Industries (AMID) is interested on putting the sector on the map. Could you please tell us a bit more about…

regulator The technical & RA director and the managing director of Qually Corporacion explain how authorized third partied act as an extension of the regulative body, Cofepris, helping to assure that generics obtain a certain standard before they are released on the market, that is why the main challenge is to…

MSD The managing director of MSD in Mexico explains why the Mexican pharmaceutical market is an attractive market in which to compete, but not one that will deliver 12 to 15 percent growth year on year, why 2014 has been a tough year for the sector and how MSD is focusing…

Parexel Claudio Soto, general manager of PAREXEL Mexico, discusses how the clinical research process required to receive approval for a new clinical protocol in Mexico is fairly straightforward compared to other countries in Latin America. She also addresses the government´s increasing awareness of the importance of their role in helping to…

consulting The managing partner of a specialist boutique PR and integrated communications management agency serving the local pharma sector unveils his theory of holistic, industry-wide lobbying and gives some pointers as to the business winds and emergent growth spots in the local market. Maybe you could start by telling us a…

GSK The general manager of a British pharma giant with over 25 years of presence in Romania discusses how vaccination programs can play a significant role in increasing the cost-effectiveness of the national healthcare system. She also outlines her company’s CSR initiatives to stem the migratory outflow of medical professionals. How have…

CRO The directors of one of the leading in country contract research organisations, explain exactly what makes Romania such an attractive destination for clinical trials. They also give some indications of how the already booming clinical research is expected to thrive, and how there will remain plenty of work for all.…